NASDAQ:BIOL - BIOLASE Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.30 +0.01 (+0.78 %)
(As of 07/18/2018 04:47 AM ET)
Previous Close$1.29
Today's Range$1.28 - $1.36
52-Week Range$1.14 - $4.60
Volume56,100 shs
Average Volume63,006 shs
Market Capitalization$26.62 million
P/E RatioN/A
Dividend YieldN/A
Beta1.55
BIOLASE logoBIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the United States and internationally. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment, including three-dimensional (3D) CAD/CAM intra-oral scanners and digital dentistry software. Its dental imaging products comprise 3Shape Trios intraoral scanners, digital impression systems, and software for taking 3D scans, which are used to design crowns, study models, surgical guides for implant placement, and event orthodontic and athletic appliances. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

Receive BIOL News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIOL
CUSIPN/A
Phone949-361-1200

Debt

Debt-to-Equity Ratio0.08
Current Ratio2.56
Quick Ratio1.54

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$46.93 million
Price / Sales0.57
Cash FlowN/A
Price / CashN/A
Book Value$1.43 per share
Price / Book0.91

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-16,850,000.00
Net Margins-38.56%
Return on Equity-66.34%
Return on Assets-40.97%

Miscellaneous

Employees195
Outstanding Shares20,480,000
Market Cap$26.62

The Truth About Cryptocurrencies

BIOLASE (NASDAQ:BIOL) Frequently Asked Questions

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

When did BIOLASE's stock split? How did BIOLASE's stock split work?

Shares of BIOLASE reverse split before market open on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

How were BIOLASE's earnings last quarter?

BIOLASE Inc (NASDAQ:BIOL) posted its earnings results on Wednesday, May, 2nd. The medical technology company reported ($0.20) earnings per share for the quarter, hitting the consensus estimate of ($0.20). The medical technology company earned $10.02 million during the quarter. BIOLASE had a negative return on equity of 66.34% and a negative net margin of 38.56%. View BIOLASE's Earnings History.

When is BIOLASE's next earnings date?

BIOLASE is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for BIOLASE.

What is the consensus analysts' recommendation for BIOLASE?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of BIOLASE's key competitors?

Who are BIOLASE's key executives?

BIOLASE's management team includes the folowing people:
  • Mr. John R. Beaver, Interim CEO, CFO & Sr. VP (Age 57)
  • Mr. Dmitri Boutoussov, VP of R&D (Age 55)
  • Mr. Richard R. Whipp, VP of Operations (Age 66)
  • Mr. William E. Brown Jr., VP of Bus. Devel. (Age 70)
  • Mr. Daniel Merkin, National Sales Director (Age 45)

Has BIOLASE been receiving favorable news coverage?

News stories about BIOL stock have trended somewhat positive on Wednesday, Accern reports. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BIOLASE earned a news sentiment score of 0.08 on Accern's scale. They also gave news coverage about the medical technology company an impact score of 46.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of BIOLASE?

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $1.30.

How big of a company is BIOLASE?

BIOLASE has a market capitalization of $26.62 million and generates $46.93 million in revenue each year. BIOLASE employs 195 workers across the globe.

How can I contact BIOLASE?

BIOLASE's mailing address is 4 CROMWELL, IRVINE CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]


MarketBeat Community Rating for BIOLASE (NASDAQ BIOL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about BIOLASE and other stocks. Vote "Outperform" if you believe BIOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.